Closing Ancillary Processes: The New Bottleneck In Cell and Gene Therapy

Source: Invetech

One of the continued challenges for scalable commercial manufacturing of cell therapies is closing and automating the entire manufacturing process. Many core manufacturing processes may be closed, but peripheral systems e.g. media formulation, viral vector packaging remain open – introducing opportunities for failures.

Invetech’s approach enables manufacturers to close and integrate both core and peripheral processes.
Invetech configures scalable automated GMP manufacturing systems for cell-based products. This includes our formulation and fill automated systems and our (to be launched) counterflow centrifuge product (CFC).
Our formulation and fill systems focus on the formulation of large-scale culture media, cell products for cryopreservation, automated bag-filling of cell products (both autologous and allogeneic) and packaging of viral vector products.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Cell & Gene